The editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk

American Journal of Cardiology

Volumn 96, Issue 11, 2005, Pages 1589-1604

  Bresalier, Robert S ^a,g   Friedewald Jr , Vincent E ^b   Rakel, Robert E ^c   Roberts, William C ^d,e   Williams, Gary W ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e BAYLOR HEALTH CARE SYSTEM   (United States)

^f SCRIPPS CLINIC   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETADOLAC; IBUPROFEN; LUMIRACOXIB; MELOXICAM; MISOPROSTOL; NABUTAMONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PROTON PUMP INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ACCREDITATION; ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTINUING EDUCATION; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; EDEMA; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG EDEMA; LUNG EMBOLISM; OSTEOARTHRITIS; PHYSIOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STROKE; THROMBOEMBOLISM; WEIGHT REDUCTION;

ALZHEIMER DISEASE; ARTHRITIS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INCIDENCE; RISK FACTORS; WORLD HEALTH;

EID: 28044443165     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.09.069     Document Type: Conference Paper

References (68)

1. U.S. Food and Drug Administration (FDA) Alert. Available at: http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm. Accessed April 7, 2005.
2. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs Nat New Biol 231 1971 232 235
3. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvein, T.J. Schnitzer Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
4. D.H. Solomon, S. Schneeweiss, R.J. Glynn, Y. Kiyota, R. Levin, H. Mogun, J. Avorn Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
5. W.A. Ray, C. Stein, J. Daugherty, K. Hall, P.G. Arbogast, M.R. Griffin COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
6. W.A. Ray, C.M. Stein, K. Hall, J.R. Daugherty, M.R. Griffin Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease an observational cohort study Lancet 359 2002 118 123
7. D.J. Graham, D. Campen, R. Hui, M. Spence, C. Cheetham, G. Levy, S. Shoor, W.A. Ray Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs nested case-control study Lancet 365 2005 475 481
8. S.P. Johnsen, H. Larsson, R.E. Tarone, J.K. McLaughlin, B. Nørgård, S. Friis, H.T. Sørensen Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs a population-based case-control study Arch Intern Med 165 2005 978 984
9. Sudbo J Lee JJ, Lippman SM, Dannenberg AJ, Sagen S, Mork J, Ristimki A, Sudbo A Kildal W, Reith A. Non-steroidal anti-inflammatory drugs, tobacco and the risk of oral cancer. Abstract 4377 presented April 18 at the 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
10. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, J.A. Baron Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
11. P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe, M. Egger Risk of cardiovascular events and rofecoxib cumulative meta-analysis Lancet 364 2004 2021 2029
12. D.H. Solomon, S. Schneeweiss, R.J. Glynn, Y. Kiyota, R. Levin, H. Mogun, J. Avorn Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
13. Merck News Release. Available at: www.merck.com/newsroom/press_releases/ product/2004_0930.html. Accessed August 3, 2005.
14. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial JAMA 284 2000 1247 1255
15. Celecoxib [package insert] 2002 GD Searle LLC, a subsidiary of Pharmacia Corporation Chicago, Il August
16. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, M. Bertagnolli Adenoma Prevention with Celecoxib (APC) Study Investigators Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
17. Levin B. FDA Advisory Board Committee Meeting. February 17, 2005: Gaithersburg, MD.
18. Clinical Trials Details. Available at: http://www.clinicaltrials.gov/ct/ show/NCT00007189?order=1. Accessed August 3, 2005.
19. B.K. Martin, C.L. Meinert, J.C. Breitner ADAPT Research Group Double placebo design in a prevention trial for Alzheimer's disease Control Clin Trials 23 2002 93 99
20. NIH Press Release on Suspension. Available at: http://www.nih.gov/news/ pr/dec2004/od-20.htm. Accessed August 3, 2005.
21. NIH Clinical Trials. Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Available at http://www.clinical%20trials.gov/ct/show/ NCT00007189?order=1. Accessed August 3, 2005.
22. N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce, K.M. Verburg Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352 2005 1081 1091
23. M.E. Farkouh, H. Kirshner, R.A. Harrington, S. Ruland, F.W. Verheugt, T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes randomized controlled trial Lancet 364 2004 675 684
24. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, R. Bresalier, G. McKeown-Eyssen, R.W. Summers, R. Rothstein A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
25. E. Ott, N.A. Nussmeir, P.C. Duke, R.O. Feneck, R.P. Alston, M.C. Snabes, R.C. Hubbard, P.H. Hsu, L.J. Saidman, D.T. Mangano Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery J Thorac Cardiovasc Surg 125 2003 1481 1492
26. C.D. Furberg, B.M. Psaty, G.A. FitzGerald Parecoxib, valdecoxib, and cardiovascular risk Circulation 111 2005 249
27. S. Alsalameh, M. Burian, G. Mahr, B.G. Woodcock, G. Geisslinger Review article the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor Aliment Pharmacol Ther 17 2003 489 501
28. February 16-18, 2005 Joint Meeting with the Arthritis Drug Advisory Committee. Transcript of February 17, 2005. Available at: http://www.fda.gov/ ohrms/dockets/ac/05/transcripts/2005-4090T2.htm. Accessed August 3, 2005.
29. Food and Drug Administration. April 6, 2005. Available at: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf. Accessed August 3, 2005.
30. G.A. Fitzgerald, C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
31. G.A. Fitzgerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
32. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, T. Grosser, J.A. Lawson, G.A. FitzGerald Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539 541
33. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
34. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
35. C.M. Weyland, J.J. Goronzy, J.J. Goronzy, G. Liuzzo, S.L. Kopecky, D.R. Holmes, R.L. Frye T-cell immunity in acute coronary syndromes Mayo Clin Proc 76 2001 1011 1020
36. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
37. R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R.E. Gay, M. Neidart Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 2003 405 409
38. M. Walter, R.F. Jacob, C.A. Day, R. Dahlborg, Y. Weng, R.P. Mason Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification comparison to sulfonamide COX-2 inhibitors and NSAIDs Atherosclerosis 177 2004 235 243
39. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, E.J. Roccella Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
40. A. Whelton, W.B. White, A.E. Bello, J.A. Puma, J.G. Fort Effects of celecoxib and rofecoxib on blood pressure and edema in patients <65 years of age with systemic hypertension and osteoarthritis Am J Cardiol 90 2002 959 963
41. MMWR: Comorbidity of high blood pressure and arthritis. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001503.htm. Accessed August 3, 2005.
42. A. Whelton, J.G. Fort, J.A. Puma, D. Normandin, A.E. Bello, K.M. Verburg Cyclooxygenase-2-specific inhibitors and cardiorenal function a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients Am J Ther 8 2001 85 95
43. W.B. White, J. Kent, A. Taylor, K.M. Verburg, J.B. Lefkowich, A. Whelton Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors Hypertension 39 2002 929 934
44. J.R. Sowers, W.B. White, B. Pitt, A. Whelton, L. Simon, N. Winner, A. Kivitz, H. van Ingen, T. Brabant, J. Fort Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type-2 diabetes mellitus Arch Intern Med 165 2005 161 168
45. P.M. Ridker, N.R. Cook, I.-M. Lee, D. Gordon, M. Gaziano, J.E. Manson, C.H. Hennekens, J.E. Buring A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
46. R.S. Eidelman, P.R. Hebert, S.E. Weisman, C.H. Hennekens An update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 163 2003 2006 2010
47. F. Catella-Lawson, P.R. Muredach, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas, G.A. FitzGerald Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
48. T.M. MacDonald, L. Wei Effect of ibuprofen on cardioprotective effect of aspirin Lancet 306 2003 573 574
49. A. Lanas, R.S. Bresalier, R. Sandler, J. Bolognese, H. Qan, B. Oxenius, K. Horgan, R. Riddell, D. Morton, J.A. Baron Upper gastrointestinal events associated with rofecoxib in a colorectal adenoma chemoprevention trial Gastroenterology 129 2005 371
50. M.L. Capone, S. Tacconelli, M.G. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P.D. Gregorio, G. Merciaro, C. Patrono, P. Patrignani Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects Circulation 109 2004 1468 1471
51. M. Hermann, H. Krum, F. Ruschitzka To the heart of the matter coxibs, smoking, and cardiovascular risk Circulation 112 2005 941 945
52. J.P. Kelly, D.W. Kaufman, J.M. Jurgelon, J. Sheehan, R.S. Koff, S. Shapiro Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product Lancet 348 1996 1413 1416
53. E. Rahme, A. Barkun, Y. Toubouti, S. Rochon, J. LeLorier Do proton pump inhibitors (PPI) infer additional gasrointestinal protection in patients given celecoxib? Pharmacoepidemiology and Drug Safety 14 2005 S189
54. L. Laine, E.S. Maller, C. Yu, H. Quan, T. Simon Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition a double blind trial Gastroenterology 127 2004 395 402
55. D.Y. Graham, N.M. Agrawal, D.R. Campbell, M.M. Haber, C. Collis, N.L. nLukasik, B. Huang Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs results of a doubleblind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole Arch Intern Med 162 2002 169 175
56. A.J. Dannenberg, K. Subbaramaiah Targeting cyclooygenase-2 in human neoplasia rationale and promise Cancer Cell 4 2003 431 443
57. G. Steinbach, P.M. Lynch, R.K.S. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, B. Levin The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
58. Celecoxib Treatment for Lung Cancer. Available at: http://www. clinicaltrials.gov/ct/show/NCT00108186?order=1. Accessed August 3, 2005.
59. A.G. Johnson, T.V. Nguyen, R.O. Day Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 121 1994 289 300
60. E.J. Topol Failing the public health - rofecoxib, Merck, and the FDA N Engl J Med 351 2004 1707 1709
61. N.V. Chandrasekharan, H. Dai, L.T. Roos, N.K. Evanson, J. Tomsik, D.L. Simmon COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs CLoning, structure and expression Proc Natl Acad Sci USA 99 2002 13926 13931
62. T.V. Perneger, P.K. Whelton, M.J. Klag Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs N Engl J Med 331 1994 1675 1679
63. G.C. Curhan, E.L. Knight, B. Rosner, S.E. Hankinson, M.J. Stampfer Lifetime nonnarcotic analgesic use and decline in renal function in women Arch Intern Med 164 2004 1519 1524
64. J.P. Forman, M.J. Stampfer, G.C. Curhan Non-narcotic analgesic dose and risk of incident hypertension in US women Hypertension 46 2005 500 507
65. L.A. Garcia Rodriguez, S. Hernandez-Diaz Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs Epidemiology 12 2001 570 576
66. E. Rahme, D. Pettitt, J. LeLorier Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population Arthritis Rheum 46 2002 3046 3054
67. A.D. Woolf, H. Zeidler, U. Haglund, A.J. Carr, S. Chaussade, D. Cucinotta, D.J. Veale, E. Martin-Mola Arthritis Action Group Musculoskeletal pain in Europe its impact and a comparison of population and medical perceptions of treatment in eight European countries Ann Rheum Dis 63 2004 342 347
68. T. Pincus, C. Swearingen, P. Cummins, L.F. Callahan Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both drugs in patients with osteoarthritis J Rheumatol 27 2000 1020 1027